No randomized studies have directly compared treatment with burosumab, a monoclonal antibody targeting FGF23, with oral phosphate and active vitamin D in adults with XLH. This three-year analysis ...
Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results